The chief executive of the biotechnology industry’s top lobbying group in Washington is on leave amid dissent within the organization about its direction and concern about its results, according to people familiar with the group.
“The BIO CEO is currently on leave,” a spokesman for the Biotechnology Innovation Organization said in response to inquiries from The Wall Street Journal. He declined to comment further.
